HomeCompareCYTO vs PFE

CYTO vs PFE: Dividend Comparison 2026

CYTO yields 666.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYTO wins by $608115.61M in total portfolio value
10 years
CYTO
CYTO
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full CYTO calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CYTO vs PFE

📍 CYTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTOPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYTO + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYTO pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTO
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CYTO beats the other by $399,126,843,673.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTO + PFE for your $10,000?

CYTO: 50%PFE: 50%
100% PFE50/50100% CYTO
Portfolio after 10yr
$304057.85M
Annual income
$234,780,522,537.48/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CYTO
No analyst data
Altman Z
-1.2
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTO buys
0
PFE buys
0
No recent congressional trades found for CYTO or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTOPFE
Forward yield666.67%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$608115.66M$49.6K
Annual income after 10y$469,561,018,816.25$26,258.71
Total dividends collected$596792.85M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CYTO vs PFE ($10,000, DRIP)

YearCYTO PortfolioCYTO Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$77,367$66,666.67$9,153$693.39+$68.2KCYTO
2$564,818$482,035.31$8,593$849.25+$556.2KCYTO
3$3,893,246$3,288,890.67$8,336$1,066.78+$3.88MCYTO
4$25,352,760$21,186,987.16$8,437$1,384.80+$25.34MCYTO
5$156,070,781$128,943,327.59$9,013$1,875.40+$156.06MCYTO
6$908,837,800$741,842,064.29$10,306$2,680.72+$908.83MCYTO
7$5,009,769,782$4,037,313,336.56$12,820$4,101.38+$5009.76MCYTO
8$26,159,339,258$20,798,885,591.56$17,673$6,826.70+$26159.32MCYTO
9$129,490,317,125$101,499,824,118.87$27,543$12,591.86+$129490.29MCYTO
10$608,115,658,140$469,561,018,816.25$49,560$26,258.71+$608115.61MCYTO

CYTO vs PFE: Complete Analysis 2026

CYTOStock

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Full CYTO Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CYTO vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTO vs SCHDCYTO vs JEPICYTO vs OCYTO vs KOCYTO vs MAINCYTO vs JNJCYTO vs MRKCYTO vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.